[HTML] frontiersin.org

[HTML][HTML] Discovery of SIRT7 inhibitor as new therapeutic options against liver cancer

C Zhang, Y Li, B Liu, C Ning, Y Li, Y Wang… - Frontiers in cell and …, 2022 - frontiersin.org
Optimal therapeutic strategies for liver cancer patients remain challenging due to the high
recurrence rate after surgical resection and chemotherapy resistance. Emerging evidence …
被引用次数：23 相关文章
[HTML] nih.gov

[HTML][HTML] Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer

C Zhang, Y Li, B Liu, C Ning, Y Li… - Frontiers in Cell and …, 2021 - ncbi.nlm.nih.gov
Optimal therapeutic strategies for liver cancer patients remain challenging due to the high
recurrence rate after surgical resection and chemotherapy resistance. Emerging evidence …

Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer

C Zhang, Y Li, B Liu, C Ning, Y Li, Y Wang, Z Li - 2022 - agris.fao.org
Optimal therapeutic strategies for liver cancer patients remain challenging due to the high
recurrence rate after surgical resection and chemotherapy resistance. Emerging evidence …

Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer

C Zhang, Y Li, B Liu, C Ning, Y Li… - Frontiers in cell and …, 2022 - pubmed.ncbi.nlm.nih.gov
Optimal therapeutic strategies for liver cancer patients remain challenging due to the high
recurrence rate after surgical resection and chemotherapy resistance. Emerging evidence …

Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer.

C Zhang, Y Li, B Liu, C Ning, Y Wang… - Frontiers in Cell and …, 2022 - europepmc.org
Optimal therapeutic strategies for liver cancer patients remain challenging due to the high
recurrence rate after surgical resection and chemotherapy resistance. Emerging evidence …

Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer.

C Zhang, Y Li, B Liu, C Ning, Y Wang… - Frontiers in Cell and …, 2022 - europepmc.org
Optimal therapeutic strategies for liver cancer patients remain challenging due to the high
recurrence rate after surgical resection and chemotherapy resistance. Emerging evidence …